利妥昔单抗生物类似药——rituximab-abbs  

The biosimilar of rituximab——rituximab-abbs

作　　者：王琪 方翼[1] WANG Qi;FANG Yi(Department of Pharmacy,Peking University People's Hospital,Beijing 100044,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Science,Peking University,Beijing 100083,China)

机构地区：[1]北京大学人民医院药剂科,北京100044 [2]北京大学医学部药学院药事管理与临床药学系,北京100083

出　　处：《临床药物治疗杂志》2019年第10期5-9,共5页Clinical Medication Journal

摘　　要：Rituximab-abbs是利妥昔单抗的生物类似药,也是美国食品药品监督管理局批准的首个利妥昔单抗生物类似药,目前该药已相继在韩国、欧洲、美国以及加拿大上市,主要用于治疗成人非霍奇金淋巴瘤等血液系统恶性肿瘤、类风湿性关节炎以及肉芽肿性血管炎和显微镜下多血管炎。尽管生物类似药与原研药在结构及临床特性上均高度相似,但其有效性及安全性问题仍需予以重视。为加深临床工作者对该药的理解,本文针对其药理机制、药动学特性及临床应用等作一综述。Rituximab-abbs is a biosimilar of rituximab,also the first rituximab biosimilar approved by FDA.Currently,it has been marketed in Korea,Europe,America and Canada The main indications of rituximab-abbs include lymphoid and hematopoietic systems malignant tumor like Non-Hodgkin’s lymphoma,rheumatoid arthritis,granulomatosis with polyangiitis,and microscopic polyangiitis.Though a biosimilar is highly similar to its original drug in molecule structure and clinical profiles,attention should still be paid to its efficacy and safety.To get better understandingof this drug,this paper reviewed its mechanism of action,pharmacokinetics and clinical application.

关 键 词：rituximab-abbs 利妥昔单抗 药动学 药效学 安全性 

分 类 号：R979.19[医药卫生—药品]